Solid Biosciences Inc. (SLDB) — Stock Price, Chart & Analysis
Solid Biosciences Inc. (SLDB) is a Healthcare stock currently trading at $8.92, up 4.45% on the day. It carries a market capitalization of $956.45M. Over the past 52 weeks, SLDB has traded between $3.79 and $11.45. Solid Biosciences Inc. does not currently pay a regular dividend. View the live SLDB chart, technical opinion, analyst ratings, fundamentals and latest news below.
Solid Biosciences Inc. (SLDB) key data
| Price | $8.92 |
| Change (today) | +4.45% |
| Previous close | $8.54 |
| Market cap | $956.45M |
| EPS (TTM) | $-1.97 |
| 52-week high | $11.45 |
| 52-week low | $3.79 |
| Beta | 2.44 |
| Avg. volume | 1.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Solid Biosciences Inc. (SLDB)
How much does one share of Solid Biosciences Inc. cost?
As of the latest update, one share of Solid Biosciences Inc. (SLDB) trades at $8.92 (+4.45% today).
What is Solid Biosciences Inc.'s market cap?
Solid Biosciences Inc. has a market capitalization of approximately $956.45M.
What is Solid Biosciences Inc.'s earnings per share (EPS)?
Solid Biosciences Inc.'s trailing twelve-month EPS is $-1.97.
Does Solid Biosciences Inc. pay a dividend?
Solid Biosciences Inc. does not currently pay a regular dividend.
What is Solid Biosciences Inc.'s 52-week trading range?
Over the past year, SLDB has traded between $3.79 and $11.45.
What is the analyst price target for Solid Biosciences Inc.?
The mean analyst price target for Solid Biosciences Inc. is $18.62. This is informational only and not investment advice.
Latest Solid Biosciences Inc. (SLDB) news
- Solid Biosciences to Participate at Upcoming Investor ConferencesNews · Sep 2, 2026
- Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?News · Jul 2, 2026
- Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and AnalyticsNews · Jun 2, 2026
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)News · Jun 1, 2026
- Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesNews · May 12, 2026
- Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyNews · May 7, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live SLDB dashboard…